Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus

Status Recruiting

Clinical Trial Summary

The purpose of this study is to address the pharmacokinetic (PK) profiles of everolimus and tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per day of everolimus in fixed doses. For comparison purposes, pharmacokinetic profiles will be performed at first dose (abbreviated), 4th day, 14th day, and 42nd day post-transplantation.

Clinical Trial Description

To address the pharmacokinetic profiles of everolimus and tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per day of everolimus in fixed doses. For comparison purposes, pharmacokinetic profiles will be performed at first dose (abbreviated), 4th day, 14th day, and 42nd day post-transplantation. Patients will receive triple therapy steroids, tacrolimus and everolimus. Tacrolimus will be administered at a dose of 0.15 mg/kg/day to achieve 10-15 ng/ml 14 days, and 5-10 thereafter. During the first 6 weeks (the PK study period) everolimus will be assigned to fixed dose of 0.75 or 1.5 mg bid. After day 42, everolimus will be adjusted for 3-8 ng/ml and tacrolimus minimized to optimize graft function. Efficacy and safety parameters at 6 months post-transplantation will be secondary endpoints. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Kidney Diseases

Clinical Trial Details

NCT number	NCT00325325
Study type	Interventional
Source	Hospital Universitario Ramon y Cajal
Contact	Julio Pascual, MD
Phone	+34 91 3368018
Email	julpascual@gmail.com
Status	Recruiting
Phase	Phase 2
Start date	January 2006
Completion date	June 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03246984` - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ	N/A
Completed	`NCT03545113` - Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease	N/A
Recruiting	`NCT05100017` - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure	N/A
Recruiting	`NCT04559321` - Holmium Vs Trilogy Kidney Stones GUY's 1-2	Phase 3
Recruiting	`NCT05036850` - China Kidney Patient Trials Network
Completed	`NCT04037436` - Functional Exercise and Nutrition Education Program for Older Adults	N/A
Active, not recruiting	`NCT01529658` - Renal Hypothermia During Partial Nephrectomy	N/A
Completed	`NCT01679587` - Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)	Phase 1
Completed	`NCT01155141` - Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH	Phase 4
Completed	`NCT00755690` - Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease	N/A
Recruiting	`NCT05759754` - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease	N/A
Completed	`NCT03213158` - Ixazomib for Desensitization	Phase 2
Active, not recruiting	`NCT02237352` - Mechanisms of Diabetic Nephropathy in Ecuador
Recruiting	`NCT06067867` - Kidney and Pregnancy Registry
Recruiting	`NCT04110080` - Enhanced Recovery After Surgery in Kidney Transplant Donors	N/A
Active, not recruiting	`NCT04876963` - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Enrolling by invitation	`NCT05324878` - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Active, not recruiting	`NCT04631965` - Healthcare Transition of Adolescents With Chronic Health Conditions
Completed	`NCT03394859` - Electronic Medical Records and Genomics (eMERGE) Phase III